Cargando…

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

A population pharmacokinetic analysis of delamanid and its major metabolite DM-6705 was conducted to characterize the pharmacokinetics of delamanid and DM-6705 in pediatric participants with multidrug-resistant tuberculosis (MDR-TB). Data from participants between the ages of 0.67 and 17 years, enro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Tomohiro, Svensson, Elin M., Wang, Xiaofeng, Wang, Yanlin, Hafkin, Jeffrey, Karlsson, Mats O., Mallikaarjun, Suresh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846319/ https://www.ncbi.nlm.nih.gov/pubmed/34843388 http://dx.doi.org/10.1128/AAC.01608-21

Ejemplares similares

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Wang, Xiaofeng, et al.
Publicado: (2020)

Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Mallikaarjun, Suresh, et al.
Publicado: (2020)

Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial
por: Garcia-Prats, Anthony J., et al.
Publicado: (2022)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
por: Hafkin, Jeffrey, et al.
Publicado: (2017)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects
por: Mallikaarjun, Suresh, et al.
Publicado: (2016)

Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis
por: Tanneau, Lénaïg, et al.
Publicado: (2021)

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
por: Skripconoka, Vija, et al.
Publicado: (2013)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832
por: Dawson, Rodney, et al.
Publicado: (2023)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients
por: Modongo, Chawangwa, et al.
Publicado: (2015)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
por: Wang, Xiaofeng, et al.
Publicado: (2022)

Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments
por: Liu, Yongge, et al.
Publicado: (2023)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
por: Nasiri, Mohammad Javad, et al.
Publicado: (2022)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT/QTc Intervals in Healthy Subjects
por: Gupta, Vipul K., et al.
Publicado: (2021)

Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis
por: Khoshnood, Saeed, et al.
Publicado: (2021)

The Activities and Secretion of Cytokines Caused by Delamanid on Macrophages Infected by Multidrug-Resistant Mycobacterium tuberculosis Strains
por: Lyu, Xia-Li, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function
por: Shoaf, Susan E, et al.
Publicado: (2014)

Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis
por: Tanneau, Lénaïg, et al.
Publicado: (2020)

Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis
por: Zhao, Yanan, et al.
Publicado: (2018)

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
por: Yang, Jeong Seong, et al.
Publicado: (2018)

An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment
por: Francis, Jose, et al.
Publicado: (2020)

Adverse Drug Reaction Monitoring in Multidrug-Resistant Tuberculosis Patients Receiving Bedaquiline and Delamanid-Based Regimen
por: Paikray, Elisha, et al.
Publicado: (2022)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021)

Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
Publicado: (2019)

An Integrated Pharmacokinetic–Pharmacodynamic–Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia
por: Piena, Marjanne A., et al.
Publicado: (2021)

Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
por: Purohit, Vivek S., et al.
Publicado: (2018)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
por: Rodriguez, Carly A., et al.
Publicado: (2023)

Assessing QTc Effects of Vericiguat Using Two Different Concentration-QTc Modeling Approaches
por: Ruehs, Hauke, et al.
Publicado: (2023)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

The role of delamanid in the treatment of drug-resistant tuberculosis
por: Lewis, Joseph M, et al.
Publicado: (2015)

Preclinical Pharmacokinetics and Safety of Intravenous RTD-1
por: Park, A. Young J., et al.
Publicado: (2022)

Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis)
por: Overcash, J. Scott, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hlb7khoauadm08avtno049a7pp